Delcath Systems Inc
NASDAQ:DCTH
DCTH's latest stock split occurred on Dec 24, 2019
The company executed a 1-for-700 stock split, meaning that for every 700 shares held, investors received 1 new share.
Before the split, DCTH traded at 0.0411 per share. Afterward, the share price was about 28.77.
The adjusted shares began trading on Dec 24, 2019. This was DCTH's 5th stock split, following the previous one in May 2, 2018.
BGLC
ATORX
TGL
Delcath Systems Inc
Glance View
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.
You don't have any saved screeners yet